Wu J S, Hwang L Y, Goodman K J, Beasley R P
University of Texas-Houston, School of Public Health, Baylor College of Medicine, USA.
J Infect Dis. 1999 Jun;179(6):1319-25. doi: 10.1086/314768.
The long-term efficacy of hepatitis B vaccination among high-risk infants was determined in 805 vaccine responders, immunized at birth in Taiwan during 1981-1984 and followed to age 10 years, via life table survival and Cox multivariate analyses. At 10 years, cumulative persistence of antibody to hepatitis B surface antigen (anti-HBs) was 85%, and cumulative incidence of hepatitis B virus (HBV) infection was 15%. Three children became carriers. Twelve-month anti-HBs titer was the strongest predictor of efficacy. The higher the initial titer, the lower the risk of anti-HBs loss (relative risk [RR], 0.26 for titer of 100-999 mIU/mL; RR, 0.08 for titer >1000 mIU/mL; P<.001) and HBV infection (RR, 0.55 and 0.27; P<.05). Maternal hepatitis B e antigen positivity but not hepatitis B immunoglobulin dose or gender predicted greater antibody persistence to age 10 years. Because the level of antibody persistence remained high and few became carriers, booster revaccination within 10 years seems unnecessary.
通过生命表生存分析和Cox多变量分析，对1981年至1984年在台湾出生时接种疫苗并随访至10岁的805名疫苗应答者进行了研究，以确定高危婴儿中乙肝疫苗的长期疗效。10岁时，乙肝表面抗原抗体（抗-HBs）的累积持续率为85%，乙肝病毒（HBV）感染的累积发生率为15%。有3名儿童成为携带者。12个月时的抗-HBs滴度是疗效的最强预测指标。初始滴度越高，抗-HBs消失的风险越低（相对风险[RR]，滴度为100 - 999 mIU/mL时为0.26；滴度>1000 mIU/mL时为0.08；P<.001）以及HBV感染的风险越低（RR分别为0.55和0.27；P<.05）。母亲乙肝e抗原阳性而非乙肝免疫球蛋白剂量或性别可预测至10岁时更高的抗体持续率。由于抗体持续水平仍然很高且很少有人成为携带者，10年内似乎无需加强复种。
